Breaking News Instant updates and real-time market news.

GILD

Gilead

$67.48

0.43 (0.64%)

11:04
05/15/18
05/15
11:04
05/15/18
11:04

Gilead announces FDA approval of once-daily oral Truvada

Gilead Sciences announced that the FDA has approved once-daily oral Truvada-in combination with safer sex practices-to reduce the risk of sexually acquired HIV-1 in at-risk adolescents. The safety and efficacy profile of Truvada for HIV prevention in uninfected adults, a strategy called pre-exposure prophylaxis, or PrEP, is well established, and Truvada for PrEP was first approved for use in adults in 2012. The addition of the adolescent indication is based on a study in HIV-negative individuals 15 to 17 years of age. In the United States, adolescents and young adults 13 to 24 years of age comprised 21 percent of all new infections in 2016, according to the U.S. Centers for Disease Control and Prevention, and 81 percent of those infections were among young men who have sex with men, or YMSM. Truvada for PrEP is now indicated in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents weighing at least 35 kg. Individuals must have a negative HIV test immediately prior to initiating Truvada for PrEP. Truvada has a boxed warning in its product label regarding the risks of post treatment acute exacerbation of hepatitis B and the risk of drug resistance with the use of Truvada for PrEP in undiagnosed early HIV infection. Further important safety information, adverse drug reactions and prescribing considerations are included below.

  • 15

    May

  • 18

    May

  • 21

    May

GILD Gilead
$67.48

0.43 (0.64%)

03/21/18
MSCO
03/21/18
NO CHANGE
Target $209
MSCO
Equal Weight
Bluebird Bio price target to $209 from $152 at Morgan Stanley
Morgan Stanley analyst Matthew Harrison raised his price target on Bluebird Bio (BLUE) to $209 from $152, stating that he now expects BCMA therapies to take 50% of the third line market by 2030 and noting that bb2121 has 50% market share there. The new assumptions increase his peak sales forecast to about $2.6B from about $1B, he pointed out. However, Harrison keeps an Equal Weight rating on Bluebird, stating that he would expect new data to be available at ASCO in June, but would also expect to see competitor data potentially from Celgene's (CELG) Juno, Gilead's (GILD) Kite, Johnson & Johnson's (JNJ) Nanjing Legend and others.
05/02/18
LEER
05/02/18
NO CHANGE
Target $72
LEER
Market Perform
Gilead price target lowered to $72 from $80 at Leerink
Leerink analyst Geoffrey Porges lowered his price target for Gilead to $72 from $80 after the company reported Q1 results and produced the first "significant disappointment" of the large cap biotech earnings season. The analyst reiterates a Market Perform rating on the shares.
05/02/18
JEFF
05/02/18
NO CHANGE
Target $95
JEFF
Buy
Gilead turnaround thesis unchanged after Q1 results, says Jefferies
Jefferies analyst Michael Yee says that while Gilead Sciences last night didn't report the best quarter, the turnaround thesis remains unchanged. The results won't prove the thesis to bears, but Gilead's turnaround is underway and should play out over the next four quarters, Yee tells investors in a post-earnings research note. The stock, trading at an 11-12 times price-to-earnings ratio, is "cheap" and the worst is mostly behind the company, Yee adds. He keeps a Buy rating on Gilead with a $95 price target.
05/02/18
MAXM
05/02/18
NO CHANGE
Target $89
MAXM
Buy
Gilead price target lowered to $89 from $94 at Maxim
Maxim analyst Jason McCarthy lowered his price target on Gilead to $89 after the company's Q1 results missed consensus, driven by lower than expected HIV/HBV revenues. The analyst has also reduced his FY18 EPS view to $6.14 from $6.74 and revenue to $20.5B from $21.4B, adding that while CAR-T treatment is promising, it is still a long way away. McCarthy keeps his Buy rating on Gilead, noting the company's "multiple" catalysts in 2018-2019 along with its $32B cash cushion that can expand the pipeline through M&A.

TODAY'S FREE FLY STORIES

MBWM

Mercantile Bank

$32.28

0.59 (1.86%)

06:17
10/16/18
10/16
06:17
10/16/18
06:17
Hot Stocks
Mercantile Bank announces 75c special cash dividend »

Mercantile Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

HF

HFF Inc.

$36.99

0.6 (1.65%)

06:17
10/16/18
10/16
06:17
10/16/18
06:17
Hot Stocks
HFF sells Sheraton Denver Downtown Hotel »

Holliday Fenoglio Fowler…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBY

Best Buy

$73.00

0.51 (0.70%)

, SHLD

Sears

$0.31

-0.0901 (-22.52%)

06:16
10/16/18
10/16
06:16
10/16/18
06:16
Recommendations
Best Buy, Sears analyst commentary  »

Best Buy to be major…

BBY

Best Buy

$73.00

0.51 (0.70%)

SHLD

Sears

$0.31

-0.0901 (-22.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDAIF

Daimler AG

$0.00

(0.00%)

, BMWYY

BMW

$0.00

(0.00%)

06:16
10/16/18
10/16
06:16
10/16/18
06:16
Periodicals
Daimler, BMW offer concessions to ease EU antitrust concerns, Reuters reports »

Germany luxury automakers…

DDAIF

Daimler AG

$0.00

(0.00%)

BMWYY

BMW

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPR

Tapestry

$43.09

-0.72 (-1.64%)

06:16
10/16/18
10/16
06:16
10/16/18
06:16
Upgrade
Tapestry rating change  »

Tapestry upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

SYMC

Symantec

$19.78

0.19 (0.97%)

06:15
10/16/18
10/16
06:15
10/16/18
06:15
Upgrade
Symantec rating change  »

Symantec upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 06

    Dec

BLK

BlackRock

$427.40

-0.18 (-0.04%)

06:14
10/16/18
10/16
06:14
10/16/18
06:14
Hot Stocks
BlackRock CEO: Q3 results highlight resilience of our differentiated platform »

Laurence Fink, Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

TWLO

Twilio

$76.26

1.27 (1.69%)

, SEND

SendGrid

$30.94

0.04 (0.13%)

06:14
10/16/18
10/16
06:14
10/16/18
06:14
Recommendations
Twilio, SendGrid analyst commentary  »

Twilio should be bought…

TWLO

Twilio

$76.26

1.27 (1.69%)

SEND

SendGrid

$30.94

0.04 (0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

MBWM

Mercantile Bank

$32.28

0.59 (1.86%)

06:13
10/16/18
10/16
06:13
10/16/18
06:13
Earnings
Mercantile Bank reports Q3 EPS 61c, consensus 61c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

BLK

BlackRock

$427.40

-0.18 (-0.04%)

06:12
10/16/18
10/16
06:12
10/16/18
06:12
Hot Stocks
BlackRock reports $11B of quarterly long-term net inflows in Q3 »

Led by iShares, active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

BLK

BlackRock

$427.40

-0.18 (-0.04%)

06:11
10/16/18
10/16
06:11
10/16/18
06:11
Hot Stocks
BlackRock reports Q3 AUM $6.4T, up 8% y/y »

Including $28B of net AUM…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

ADBE

Adobe

$238.05

-10.84 (-4.36%)

06:11
10/16/18
10/16
06:11
10/16/18
06:11
Recommendations
Adobe analyst commentary  »

Adobe remains a top pick…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$133.75

-0.03 (-0.02%)

, SNY

Sanofi

$43.45

0.56 (1.31%)

06:10
10/16/18
10/16
06:10
10/16/18
06:10
Periodicals
Pharma pushes back against required listing of drug prices in TV ads, WSJ says »

The pharmaceutical…

JNJ

Johnson & Johnson

$133.75

-0.03 (-0.02%)

SNY

Sanofi

$43.45

0.56 (1.31%)

RHHBY

Roche

$0.00

(0.00%)

AZN

AstraZeneca

$37.46

0.31 (0.83%)

PFE

Pfizer

$43.11

-0.67 (-1.53%)

LLY

Eli Lilly

$110.69

0.2 (0.18%)

MRK

Merck

$69.46

-0.31 (-0.44%)

GSK

GlaxoSmithKline

$38.87

0.56 (1.46%)

NVS

Novartis

$83.14

0.37 (0.45%)

BMY

Bristol-Myers

$57.59

0.09 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 24

    Dec

  • 11

    Jan

  • 28

    Jan

  • 16

    Feb

  • 22

    Mar

  • 28

    Apr

AMZN

Amazon.com

$1,760.99

-27.64 (-1.55%)

06:10
10/16/18
10/16
06:10
10/16/18
06:10
Periodicals
Amazon's announcement of HQ2 'imminent,' Recode reports »

Amazon's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 25

    Oct

UTHR

United Therapeutics

$123.41

0.26 (0.21%)

, MNKD

MannKind

$1.66

0.06 (3.75%)

06:10
10/16/18
10/16
06:10
10/16/18
06:10
Hot Stocks
United Therapeutics, MannKind announce closing of license agreement »

United Therapeutics…

UTHR

United Therapeutics

$123.41

0.26 (0.21%)

MNKD

MannKind

$1.66

0.06 (3.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLK

BlackRock

$427.40

-0.18 (-0.04%)

06:09
10/16/18
10/16
06:09
10/16/18
06:09
Earnings
BlackRock reports Q3 adjusted EPS $7.52, consensus $6.84 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

JBHT

J.B. Hunt

$111.78

2.52 (2.31%)

06:08
10/16/18
10/16
06:08
10/16/18
06:08
Hot Stocks
J.B. Hunt CFO says Oct peak season freight should be 'very normal', Dec 'strong' »

In its conference call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

LN

Line Corp.

$35.10

-0.81 (-2.26%)

06:07
10/16/18
10/16
06:07
10/16/18
06:07
Upgrade
Line Corp. rating change  »

Line Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$11.42

0.03 (0.26%)

06:06
10/16/18
10/16
06:06
10/16/18
06:06
Upgrade
Noodles & Company rating change  »

Noodles & Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$0.00

(0.00%)

, AUDVF

Audi AG

$0.00

(0.00%)

06:06
10/16/18
10/16
06:06
10/16/18
06:06
Hot Stocks
Volkswagen reports negative special items from Audi administrative order »

Volkswagen (VLKAY)…

VLKAY

Volkswagen

$0.00

(0.00%)

AUDVF

Audi AG

$0.00

(0.00%)

POAHY

Porsche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$121.06

-1.61 (-1.31%)

06:06
10/16/18
10/16
06:06
10/16/18
06:06
Recommendations
Wayfair analyst commentary  »

Piper reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 03

    Mar

GOV

Government Properties

06:04
10/16/18
10/16
06:04
10/16/18
06:04
Upgrade
Government Properties rating change  »

Government Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

SNN

Smith & Nephew

$34.14

-0.42 (-1.22%)

06:04
10/16/18
10/16
06:04
10/16/18
06:04
Downgrade
Smith & Nephew rating change  »

Smith & Nephew…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNKD

MannKind

$1.66

0.06 (3.75%)

, UTHR

United Therapeutics

$123.41

0.26 (0.21%)

06:04
10/16/18
10/16
06:04
10/16/18
06:04
Hot Stocks
MannKind and United Therapeutics close pending worldwide agreement »

United Therapeutics…

MNKD

MannKind

$1.66

0.06 (3.75%)

UTHR

United Therapeutics

$123.41

0.26 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRX

Amneal Pharmaceuticals

$18.73

-0.08 (-0.43%)

06:03
10/16/18
10/16
06:03
10/16/18
06:03
Downgrade
Amneal Pharmaceuticals rating change  »

Amneal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 28

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.